| Revenue growth | FY26 13.5% YoY; Q4 14.6% YoY. |
|---|---|
| Margins | FY26 EBITDA margin at 20.4%; guided 20-21% for FY27. |
| Demand visibility | Strong traction in chronic segments and international markets. |
| Management confidence | High; citing landmark year and successful new launches. |
Growth
Q4 revenue grew 14.6% YoY to INR 36,033m. FY26 revenue at INR 147,123m (up 13.5%) with 20.4% EBITDA margins.
Outlook
Targets 100-150 bps outperformance over Indian Pharma Market growth. FY27 EBITDA margins guided between 20-21%.
Risks
Geopolitical instability, increased logistics costs, and pricing pressure on APIs and packaging materials.
Earnings Call filed with BSE, NSE: ALKEM. Summary written with AI assistance from the document.
Alkem Laboratories Ltd: key numbers
- Share price
- ₹5,274.00
- Market cap
- ₹63,059 Cr
- Revenue (annual)
- ₹14,712 Cr
- Net profit (annual)
- ₹2,302 Cr
- P/E (TTM)
- 29.2×Sector 50.4×
- Promoter holding
- 49.70%-1.50% QoQ
- FII holding
- 10.42%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alkem Laboratories Ltd
All →Alkem Laboratories Management Change
Alkem Laboratories CFO Nitin Agrawal resigned effective 30 September 2026 for new opportunities. He was also a Key Managerial Personnel of the company.
Alkem Laboratories Debt & Borrowing: ₹593.5 Cr
Alkem Laboratories issued a Corporate Guarantee of Euro 54.45 Million to HSBC UK Bank for a Euro 49.5 Million term loan taken by its subsidiary, Occlutech Holding.
- Value
- ₹593.5 Cr
Alkem Laboratories Product Launch
Alkem launches NeuCeno (cenobamate), an anti-seizure medication for partial-onset seizures in adults, for the first time in India. The once-daily drug is available in six tablet strengths.
Alkem Laboratories Management Change
Alkem Laboratories has appointed Dr. Shubhadeep Sinha as a Senior Management Personnel, effective September 15, 2026. This appointment falls under standard senior management disclosures.
Alkem Laboratories Product Launch
Alkem launched Renocia Exo, a patented exosome-based hair growth serum. It expands the company's dermatology portfolio with a new follicle-support therapy.
Alkem Laboratories Investor Presentation: Key Takeaways
Alkem reported Q1FY27 revenue of INR 3,740cr, up 11% YoY. India sales grew 10.3%, while International jumped 16%. EBITDA margin stood at 20.5%. Net profit declined 21.7% due to taxation.
- Call
- Guides 12% growth